Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Richter Rises Most in Four Weeks on Trial Result: Budapest Mover

Gedeon Richter Nyrt., Hungary’s biggest drugmaker, rose the most in almost four weeks after its experimental antipsychotic drug cariprazine met the main goals of two late-stage studies in schizophrenia.

The shares gained as much as 4.9 percent and traded 2.9 percent higher at 39,105 forint by the close in Budapest, the biggest jump since since Feb. 2. The benchmark BUX stock index advanced 0.3 percent to 19,217.87.

Richter and its partner Forest Laboratories Inc. plan to seek approval for the drug this year to treat schizophrenia and bipolar mania, they said in a statement today. Budapest-based Richter and Forest previously reported successful late-stage trials in bipolar mania, they said.

“This is a development of great importance and the news should have a very positive impact on the stock price today,” Gergely Palffy, an equities analyst at KBC Groep NV’s broker unit in Budapest, wrote in comments sent by e-mail.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.